Linozocid 600 Tablet contains Linezolid 600 mg, an oxazolidinone-class antibiotic effective against a broad spectrum of Gram-positive bacterial infections, including resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). It functions by inhibiting bacterial protein synthesis through binding to the 23S ribosomal RNA of the 50S subunit, thereby preventing the formation of the initiation complex essential for bacterial translation. Linozocid 600 is indicated for the treatment of complicated skin and soft tissue infections, nosocomial and community-acquired pneumonia, and infections caused by susceptible strains of Gram-positive bacteria. The tablet is administered orally, with dosing typically adjusted based on the severity of infection and patient-specific factors. Common adverse effects include gastrointestinal disturbances, headache, and potential hematological abnormalities such as thrombocytopenia and anemia, necessitating periodic blood count monitoring during prolonged therapy. Caution is advised in patients with a history of serotonin syndrome, as Linezolid exhibits weak monoamine oxidase inhibitory activity. Linozocid 600 should be used under strict medical supervision to ensure appropriate use and to mitigate the risk of antibiotic resistance development.